Interpreting Failed Bioequivalence Outcomes: Regulatory and Statistical Guidance
Interpreting Failed Bioequivalence Outcomes: Regulatory and Statistical Guidance How to Interpret and Respond to Failed Outcomes in Bioequivalence Studies Introduction: When a Bioequivalence Study Fails In bioavailability and bioequivalence (BA/BE) studies, success is defined by demonstrating that the 90% confidence interval (CI) for the geometric mean ratio (GMR) of pharmacokinetic parameters—such as Cmax and AUC—falls…
Read More “Interpreting Failed Bioequivalence Outcomes: Regulatory and Statistical Guidance” »